Indoramin

This classification denotes a beta-adrenergic blocking agent with the molecular formula C22H25N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Z802HMY7H, chemically known as benzamide, n-(1-(2-indol-3-ylethyl)-4-piperidyl)- but generally known as indoramin, which bears US NIH Compound Identifier 33625. European Medicines Agency schedules Indoramin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08184MIG. The term INDORAMIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules indoramin in its Anatomical Therapeutic Chemical (ATC) Classification. INDORAMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule indoramin under HS 29333999 and SITC 51574. As of Q4 2014, INDORAMIN remains the US FDA Preferred Term for this commodity. Indoramin bears US NLM identifiers UMLS ID C0021252 and NCI Concept Code C65916. SMILES: O=C(NC1CCN(CC1)CCC1C2C([NH]C1)CCCC2)C1CCCCC1.